Double-Blind, Placebo-Controlled Study of the Therapeutic Use of Recombinant Human Erythropoietin for Anemia Associated With Chronic Renal Failure in Predialysis Patients

1991 ◽  
Vol 18 (1) ◽  
pp. 50-59 ◽  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Recombinant Human Erythropoietin ◽  
Therapeutic Use ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Erythropoietin

Recombinant Human Erythropoietin in the Treatment of the Anemia of Prematurity: Results of a Double-Blind, Placebo-Controlled Study

PEDIATRICS ◽  
1994 ◽  
Vol 93 (6) ◽  
pp. 918-923
Author(s):  
Michael P. Meyer ◽  
F. Mary Hann ◽  
Alan A. Sive ◽  
Geoffery Moller ◽  
Atties F. Malan ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Recombinant Human Erythropoietin ◽  
Reticulocyte Count ◽  
Sudden Infant Death ◽  
Controlled Study ◽  
Sudden Infant ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Erythropoietin ◽  
Anemia Of Prematurity

Objective. To assess the efficacy of recombinant human erythropoietin (rHuEpo) in the treatment of the anemia of prematurity. Methodology. A double-blind, placebo-controlled study was conducted on 80 preterm infants (≤32 weeks; postnatal age, 2 to 8 weeks; central hematocrit ≤35%). Patients were randomly assigned to receive subcutaneous rHuEpo (Eprex, 600 U/kg per week) or an equivalent volume of placebo, for up to 6 weeks. All patients received supplements of vitamin E (25 IU) and iron (3 mg/kg per day). The iron supplement was increased if declining serum ferritin measurements were noted. Results. Treatment and placebo groups did not differ significantly with respect to mean gestational age, birth weight hematocrit, or reticulocyte count at study entry. Fewer transfusions were administered to those receiving erythropoietin (7 compared with 21; P = .002). Compared with the placebo group, the infants receiving rHuEpo had a higher mean hematocrit (32.3 ± 4% vs 29.3 ± 6.2%; P = .014) and absolute reticulocyte count (223 ± 73 vs 124.9 ± 73 x 109/L; P < .001) at the end of the study. The mean neutrophil count was not significantly reduced at study exit (P = .8), nor at any other period during the trial in the rHuEpo group. Intercurrent events (mostly infections) were not increased in the treatment group, although there was one case of sudden infant death syndrome at age 4 months. Conclusions. Using a dose of rHuEpo of 600 U/kg per week, this study has shown a clear reduction in the requirement for blood transfusion in preterm infants.

scholarly journals Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure

1999 ◽  
Vol 56 (2) ◽  
pp. 674-684 ◽  
Author(s):  
Luca De Nicola ◽  
Vincenzo Bellizzi ◽  
Roberto Minutolo ◽  
Michele Andreucci ◽  
Alfredo Capuano ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Arginine Supplementation

Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin

1990 ◽  
Vol 89 (4) ◽  
pp. 432-435 ◽  
Author(s):  
Alan J. Watson ◽  
Luis F. Gimenez ◽  
Sandra Cotton ◽  
Mackenzie Walser ◽  
Jerry L. Spivak
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document